T7 Technology. GNE shall have the right, upon written notice to SG, to sublicense, at GNE's option, T7 Technology from SG nonexclusively for use with Licensed Products for human cancer uses only in the Territory, on the same terms and conditions, including payments and royalties, applicable to SG as set forth in the T7 License.
Appears in 3 contracts
Sources: Development and License Agreement (Seattle Genetics Inc /Wa), Development and License Agreement (Seattle Genetics Inc /Wa), Development and License Agreement (Seattle Genetics Inc /Wa)